

Figure S1. This study's definitions of patients with Alzheimer's disease (AD) and controls on the basis of Braak staging in the ROW discovery set. We defined cases with Braak NFT stage IV through VI and Braak amyloid stage C as AD (red-colored cells), and cases with Braak NFT stage 0 through II and Braak amyloid stage 0 or A as controls (blue-colored cells).